Related Experiment Video

Updated: Jun 17, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Ultra-short course immunotherapy in children and adolescents during a 3-yrs post-marketing surveillance study

Martin Rosewich1, Johannes Schulze, Karl J Fischer von Weikersthal-Drachenberg

  • 1Pediatric Pulmonology & Allergology, Goethe University, Frankfurt/M, Germany. Martin.Rosewich@kgu.de

Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology
|December 17, 2009
PubMed

Insights

Ultra-short course immunotherapy (uSCIT) effectively treated children and adolescents with allergic conditions. This safe and well-tolerated treatment significantly reduced medication needs and showed comparable results to adults.

Area of Science:

  • Allergy and Immunology
  • Pediatric Pulmonology
  • Pharmacovigilance

Background:

  • Ultra-short course immunotherapy (uSCIT) demonstrates efficacy and tolerability in pediatric allergic diseases.
  • Post-marketing surveillance (PMS) studies are crucial for evaluating real-world treatment outcomes.
  • Understanding juvenile subpopulation responses to uSCIT is essential for optimizing pediatric allergy care.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of uSCIT in children and adolescents with seasonal allergic rhinitis (SAR), conjunctivitis, and/or asthma.
  • To compare the efficacy of uSCIT in the juvenile subpopulation with the adult subpopulation within a PMS study.
  • To assess the impact of uSCIT on anti-allergic medication consumption in young patients.

Main Methods:

  • A prospective open study involving 422 patients aged 6-18 years with SAR, conjunctivitis, and/or asthma.
  • Administration of four pre-seasonal injections of pollen allergoids with monophosphoryl lipid A (MPL, Pollinex Quattro) over at least 3 weeks.
  • Evaluation of treatment response, anti-allergic medication use, and patient-reported tolerability, with comparisons to adult data.

Main Results:

  • 94% of pediatric patients reported good or very good treatment response, consistent with the overall study cohort.
  • Significant reduction in anti-allergic medication use from 83% to 24% after the first uSCIT course (p < 0.0001).
  • High patient acceptance (93% 'very good' or 'good') and no serious adverse events or anaphylaxis reported in the juvenile group.

Conclusions:

  • uSCIT with Pollinex Quattro exhibits comparable efficacy and tolerability in children/adolescents and adults with allergic conditions.
  • The convenient dosing schedule and favorable safety profile of uSCIT support its broader adoption in pediatric populations.
  • This PMS subanalysis confirms the value of uSCIT for managing pediatric allergic rhinitis, conjunctivitis, and asthma.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...